Do you have a link to the Q319 file?
If this is true???? then there is far more going on then anyone realized and the company is way, way undervalued?
Is this from Anavex?
I checked Edgar and nothing out there. Hmmm.
Tuesday, 12/10/19 08:48:08 AM
Re: McMagyar post# 223529 0
Post # of 223574
Think I am kidding about our piddly investments in Anavex aand why Anavex is despised by BP and Bio Institutional Investors?
this is just ONE QUARTER multiply it times 20 for five years!
Dr Missling is a planning and creative and budgetary GENIUS!]
General and Administrative (G&A) Expenses: G&A expenses, including non-cash share-based compensation costs, were $28.8 million for the three months ended September 30, 2019, compared to $7.6 million for the three months ended September 30, 2018. The increase of $21.2 million was primarily due to increases in spending to prepare for commercial launch expected in early 2020, and personnel-related costs, including non-cash share-based compensation, due to the hiring of additional personnel primarily to prepare for commercialization of our product candidates, increases in professional fees supporting ongoing business operations, and additional fees to comply with the requirements of being a public company. Our headcount, in G&A activities, increased to 119 as of September 30, 2019, compared to 23 as of September 30, 2018. Non-cash share-based compensation expense, included in personnel-related costs, was $6.3 million for the three months ended September 30, 2019, an increase of $4.4 million as compared to the same period in 2018.
Net Loss: The Company reported a net loss attributable to common shareholders for the three months ended September 30, 2019 of $106.2 million, or $2.04 per share, compared to $61.4 million, or $1.53 per share for the same period in 2018.
AI
Market Data 
Markets 
